ENDRA Life Sciences Future Growth
Future criteria checks 0/6
Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de ENDRA Life Sciences.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Medical Equipment earnings growth | 16.2% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 21 Nov 2023 |
Recent future growth updates
Recent updates
ENDRA to submit FDA De Novo request for liver disease monitoring system in coming weeks
Sep 29ENDRA Life Sciences receives European patent for TAEUS system
Aug 24Endra Life Sciences Q2 2022 Earnings Preview
Aug 12We're A Little Worried About ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate
Aug 08We're Keeping An Eye On ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate
Nov 18We Think ENDRA Life Sciences (NASDAQ:NDRA) Needs To Drive Business Growth Carefully
Jul 19ENDRA Life Sciences names Irina Pestrikova Principal Financial Officer
Jun 15ENDRA Life Sciences granted 13th U.S. Patent for its TAEUS platform technology
Jan 13ENDRA Life Sciences renews GE Healthcare collaboration agreement
Dec 21Endra Life prices $5M-share offering
Dec 16Endra Life Sciences EPS beats by $0.02
Nov 16Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 1 | -12 | N/A | -10 | 1 |
12/31/2023 | N/A | -10 | -10 | -10 | N/A |
9/30/2023 | N/A | -12 | -11 | -10 | N/A |
6/30/2023 | N/A | -12 | -11 | -11 | N/A |
3/31/2023 | N/A | -13 | -12 | -12 | N/A |
12/31/2022 | N/A | -13 | -13 | -13 | N/A |
9/30/2022 | N/A | -13 | -12 | -12 | N/A |
6/30/2022 | N/A | -12 | -12 | -12 | N/A |
3/31/2022 | N/A | -12 | -11 | -11 | N/A |
12/31/2021 | N/A | -11 | -11 | -11 | N/A |
9/30/2021 | N/A | -10 | -11 | -11 | N/A |
6/30/2021 | N/A | -11 | -10 | -10 | N/A |
3/31/2021 | N/A | -11 | -11 | -11 | N/A |
12/31/2020 | N/A | -12 | -11 | -11 | N/A |
9/30/2020 | N/A | -19 | -11 | -11 | N/A |
6/30/2020 | N/A | -19 | -11 | -11 | N/A |
3/31/2020 | N/A | -18 | -9 | -9 | N/A |
12/31/2019 | N/A | -18 | -9 | -9 | N/A |
9/30/2019 | N/A | -11 | -9 | -9 | N/A |
6/30/2019 | N/A | -10 | -8 | -8 | N/A |
3/31/2019 | N/A | -10 | -8 | -8 | N/A |
12/31/2018 | 0 | -10 | -8 | -8 | N/A |
9/30/2018 | 0 | -10 | -7 | -7 | N/A |
6/30/2018 | 0 | -8 | -6 | -6 | N/A |
3/31/2018 | 0 | -7 | -6 | -6 | N/A |
12/31/2017 | 0 | -5 | -3 | -3 | N/A |
9/30/2017 | 1 | -4 | N/A | -2 | N/A |
6/30/2017 | 1 | -4 | N/A | -2 | N/A |
3/31/2017 | 1 | -3 | N/A | -1 | N/A |
12/31/2016 | 1 | -3 | N/A | -1 | N/A |
9/30/2016 | 0 | -3 | N/A | -1 | N/A |
6/30/2016 | 1 | -2 | N/A | -1 | N/A |
3/31/2016 | 1 | -2 | N/A | -1 | N/A |
12/31/2015 | 1 | -2 | N/A | -1 | N/A |
12/31/2014 | 1 | -2 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de NDRA es superior a la tasa de ahorro (2.3%).
Beneficios frente mercado: Datos insuficientes para determinar si se prevé que los beneficios de NDRA crezcan más deprisa que el mercado US
Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de NDRA crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de NDRA crezcan más rápido que el mercado de US.
Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de NDRA crezcan a un ritmo superior a 20% al año.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de NDRA se prevé elevada dentro de 3 años.